Table 1.
Patient characteristics and clinical response to therapy.
| SCLC | NSCLC (AC) | NSCLC (SqC) | |
|---|---|---|---|
| Number | 40 | 57 | 27 |
| Age, median (IQR) | 65 (9) | 64 (15) | 67 (8) |
| Sex | |||
| Male, n (%) | 23 (57.5) | 36 (63.2) | 25 (92.6) |
| Female, n (%) | 17 (42.5) | 21 (36.8) | 2 (7.4) |
| ECOG, n (%) | |||
| 0 | 10 (25) | 35 (61.4) | 14 (51.85) |
| 1 | 26 (65) | 22 (38.6) | 13 (48.15) |
| 2 | 4 (10) | 0 | 0 |
| Smoker status | |||
| -Never-smoker | 1 (2.5) | 11 (19.3) | 1 (3.7) |
| -Smoker | 39 (97.5) | 46 (80.7) | 26 (96.3) |
| Metastases, n (%) | |||
| <3 | 17 (42.5) | 26 (45.6) | 17 (63) |
| ≥3 | 23 (57.5) | 31 (54.4) | 10 (37) |
| Brain and/or liver metastases n (%) |
22 (55) | 16 (28.6) | 6 (22.2) |
| Therapy setting: Chemotherapy |
Carboplatin + Etoposid |
Carboplatin + pemetrexed (TTF-1+) or + nab-Paclitaxel (TTF-1neg.) |
Carboplatin + nab-Paclitaxel |
| Therapy setting: ICI + others |
Atezolizumab | Pembrolizumab or (if liver metastasis) Atezolizumab + Bevacizumab |
Pembrolizumab |
| Radiation before ICI, n (%) | 4 (10) | 6 (10.5) | 3 (11.1) |
| Radiation after ICI, n (%) | 15 (37.5) | 9 (15.8) | 7 (25.9) |
| Clinical response, n (%) | |||
| -Progression/Discontinuation | 6 (15) | 14 (25) | 8 (29.6) |
| -Disease stabilization | 3 (7.5) | 10 (18) | 2 (7.4) |
| -Partial/complete response | 31 (77.5) | 32 (59) | 17 (63) |
AC—adenocarcinoma; SqC—squamous cell carcinoma; ICI—immune checkpoint inhibitor; IQR—interquartile range; TTF—thyroid transcription factor.